Andrea K Boggild, Srivicha Krudsood, Samir N Patel, Lena Serghides, Noppadon Tangpukdee, Kevin Katz, Polrat Wilairatana, W Conrad Liles, Sornchai Looareesuwan, Kevin C Kain
BACKGROUND: Despite the use of potent antimalarial drugs, the fatality rate associated with severe malaria remains high. Adjunctive therapies that target the immunopathological responses to infection may decrease mortality associated with severe malaria. We hypothesized that peroxisome proliferator-activated receptor gamma agonists (eg, rosiglitazone) would modulate the host's innate immune response to malaria and improve outcome. METHODS: In a randomized, double-blind, placebo-controlled, phase I/II trial of treatment for malaria acquired in Thailand, we investigated the safety, tolerability, and efficacy of rosiglitazone use for parasite clearance and for reducing malaria-induced inflammation...
September 15, 2009: Clinical Infectious Diseases